Skip to main content

Conference Highlights ASCO

FDA Approvals, Conference Highlights ASCO
FDA Approves Avapritinib for Advanced Systemic Mastocytosis
Read More
FDA Approvals, Conference Highlights ASCO
Pembrolizumab plus Lenvatinib Combination Receives Regular Approval for Advanced Endometrial Carcinoma
Read More
FDA Approvals, Urothelial Cancer, Conference Highlights ASCO, Oncology
Padcev Receives Regular FDA Approval for Locally Advanced or Metastatic Urothelial Cancer
Read More
Melanoma, Conference Highlights ASCO, Oncology
Novel LAG-3–Blocking Antibody plus Nivolumab Shows Promise as First-Line Treatment in Advanced Melanoma
Wayne Kuznar
Wayne Kuznar
Read More
Prostate Cancer, Conference Highlights ASCO
¹⁷⁷Lu-PSMA-617 Prolongs Survival in Patients with Metastatic Castration-Resistant Prostate Cancer
Phoebe Starr
Phoebe Starr
Read More
Conference Highlights ASCO
Early Phase 3 Results Show Survival Benefit with Nivolumab-Based Regimens in Advanced Esophageal Squamous-Cell Cancer
Wayne Kuznar
Wayne Kuznar
Read More
Renal-Cell Carcinoma, Conference Highlights ASCO, Oncology
Adjuvant Pembrolizumab Therapy Significantly Extends Disease-Free Survival in Patients with Clear-Cell Renal-Cell Carcinoma
Phoebe Starr
Phoebe Starr
Read More
Conference Highlights ASCO, Introduction
Precision Medicine and Immunotherapy Highlighted at ASCO 2018
Wayne Kuznar
Read More
Page 2 of 2
Results 11 - 18 of 18